Urinary tract infections in pregnancy

Canadian Family Physician

Volumn 54, Issue 6, 2008, Pages 853-854

  Lee, Monica ^a   Bozzo, Pina ^a   Einarson, Adrienne ^a   Koren, Gideon ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CEFALEXIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; NITROFURANTOIN; NORFLOXACIN; PENICILLIN DERIVATIVE; PHENAZOPYRIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFAMETHOXAZOLE; SULFONAMIDE; TRIMETHOPRIM;

BIRTH DEFECT; CARDIOVASCULAR DISEASE; CONGENITAL MALFORMATION; DRUG SAFETY; FETUS MALFORMATION; FIRST TRIMESTER PREGNANCY; HEMOLYTIC ANEMIA; HUMAN; NEURAL TUBE DEFECT; PREGNANCY; PRENATAL DRUG EXPOSURE; REVIEW; RISK; TERATOGENICITY; URINARY TRACT INFECTION;

ANTI-INFECTIVE AGENTS, URINARY; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; URINARY TRACT INFECTIONS;

EID: 47949115953     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Dwyer PL, O'Reilly M. Recurrent urinary tract infection in the female. Curr Opin Obstet Gynecol 2002;14(5):537-43.
2. Le J, Briggs GG, McKeown A, Bustillo G. Urinary tract infections during pregnancy. Ann Pharmacother 2004;38(10):1692-701. Epub 2004 Aug 31.
3. Christensen B. Which antibiotics are appropriate for treating bacteriuria in pregnancy? J Antimicrob Chemother 2000;46(Suppl 1):29-34.
4. Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton, MA: Publishing Sciences Group; 1977. p. 297-313, 435.
5. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005. p. 74, 268, 1153.
6. Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. Use of cephalosporins during pregnancy and in the presence of congenital abnormalities: a population-based, case-control study. Am J Obstet Gynecol 2001;184(6):1289-96.
7. Ingham B, Brentnall DW, Dale EA, McFadzean JA. Arthropathy induced by antibacterial fused N-alkyl-4-pyridone-3-carboxylic acids. Toxicol Lett 1977;1:21-6.
8. Chevais MP, Reinert P, Rondeau MC, Tobelem R, Albengres E, Riant P, et al. Critical risk/benefit analysis of pefloxacine use in children under 15 years - the problem of arthralgias. Int J Clin Pharmacol Ther Toxicol 1987;25(6):306-9.
9. Chysky V, Kapila K, Hullmann R, Arcieri G, Schacht P, Echlos R. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use. Emphasis on joint evaluation. Infection 1991;19(4):289-96.
10. Berkovitch M, Pastuszak A, Gazarian M, Lewis M, Koren G. Safety of the new quinolones in pregnancy. Obstet Gynecol 1994;84(4):535-8.
11. Pastuszak A, Andreou R, Schick B, Sage S, Cook L, Donnenfeld A, et al. New postmarketing surveillance data supports a lack of association between quinolone use in pregnancy and fetal and neonatal complications. Reprod Toxicol 1995;9:584.
12. Schaefer C, Amoura-Elefant E, Vial T, Ornoy A, Garbis H, Robert E, et al. Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). Eur J Obstet Gynecol Reprod Bio 1996;69(2):83-9.
13. Loebstein R, Addis A, Ho E, Andreou R, Sage S, Donnenfeld AE, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother 1998;42(6):1336-9.
14. Wilton LV, Pearce GL, Mann RD. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Br J Clin Pharmacol 1996;41(4):277-84.
15. Larsen H, Nielsen GL, Schønheyder HC, Olesen C, Sørensen HT. Birth outcome following maternal use of fluoroquinolones. Int J Antimicrob Agents 2001;18(3):259-62.
16. Hailey FJ, Fort H, Williams JC, Hammers B. Foetal safety of nitrofurantoin macrocrystals therapy during pregnancy: a retrospective analysis. J Int Med Res 1983;11(6):364-9.
17. Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. Nitrofurantoin and congenital abnormalities. Eur J Obstet Gynecol Reprod Biol 2001;95(1):119-26.
18. Ben David S, Einarson T, Ben David Y, Nulman I, Pastuszak A, Koren G. The safety of nitrofurantoin during the first trimester of pregnancy: meta-analysis. Fundam Clin Pharmacol 1995;9(5):503-7.
19. Gait JE. Hemolytic reactions to nitrofurantoin in patients with glucose-6-phasephate dehydrogenase deficiency: theory and practice. DICP 1990;24(12):1210-3.
20. Bruel H, Guillemant V, Saladin-Thiron C, Chabrolle JP, Lahary A, Poinsot J. [Hemolytic anemia in a newborn after maternal treatment with nitrofurantoin at the end of pregnancy.] Arch Pediatr 2000;7(7):745-7. French.
21. Sulfamethoxazole/trimethoprim [Product Monograph]. In: Repchinsky C, Editor-in-Chief. Compendium of pharmaceuticals and specialties. The Canadian drug reference for health professionals. Ottawa, ON: Canadian Pharmacists Association; 2007. p. 2254-8.
22. Sivojelezova A, Einarson A, Shuhaiber S, Koren G. Trimethoprimsulfonamide combination therapy in early pregnancy. Can Fam Physician 2003;49:1085-6.